EPISODE · May 12, 2026 · 1 MIN
AbbVie: Solid Play for Long-Term Portfolio
from The Daily News Now! Business
AbbVie, a healthcare giant spun off from Abbott Labs, boasts twelve billion-dollar products and a robust pipeline with ninety treatments in development. Its a reliable dividend stock with a 3.4% yield, having increased payouts by over 330% since the spin-off. Valuation is reasonable, with a forward P/E ratio of 14, and revenue growth of 12.4% in Q1. AbbVie is a strong long-term play for investors seeking growth and income in the healthcare sector. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/54dec8f313c1202f
NOW PLAYING
AbbVie: Solid Play for Long-Term Portfolio
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m